An Optimized Method for Single Cell Cloning of Human CAR-T Cells Based on FBS-Coated Plates.

IF 3.1 Q2 PHARMACOLOGY & PHARMACY
Advanced pharmaceutical bulletin Pub Date : 2024-12-26 eCollection Date: 2025-04-01 DOI:10.34172/apb.43798
Mahdie Jafari, Shahriyar Abdoli, Masoud Moghaddam Pour, Mohammad Ali Shokrgozar, Zahra Sharifzadeh
{"title":"An Optimized Method for Single Cell Cloning of Human CAR-T Cells Based on FBS-Coated Plates.","authors":"Mahdie Jafari, Shahriyar Abdoli, Masoud Moghaddam Pour, Mohammad Ali Shokrgozar, Zahra Sharifzadeh","doi":"10.34172/apb.43798","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>T cell-based immunotherapy, especially chimeric antigen receptor (CAR)-T cells, has emerged as an appropriate approach for treating hematologic malignancies and is currently under investigation in clinical trials for solid tumors. Despite significant improvements in CAR-T cell production processes, the isolation and expansion of CAR-engineered T cells continue to pose significant challenges. The aim of this research is to provide a simple and cost-effective method for the isolation and expansion of human CAR-T cells. This novel concept applies coated fetal bovine serum (FBS) culture plates and focuses on enhancing viability and functionality to improve the adherence of suspended T cells.</p><p><strong>Methods: </strong>This study evaluated a two-dimensional (2D) culture technique for isolating the CAR-T cells that target prostate-specific membrane antigen (PSMA) utilizing matrices pre-coated with 0.2% glutaraldehyde and FBS. Jurkat cells were transduced with a lentiviral vector encoding the anti-PSMA CAR construct. FBS-coated and commercialized Matrigel-coated matrices were used for single-cell isolation and clonal expansion. Functional tests were conducted to assess the activation and proliferation of CAR-T cells and the IFN-γ release assay subsequent to cloning and expansion.</p><p><strong>Results: </strong>Transfection efficiency markedly improved, with 88.4% of Lenti-X 293T cells demonstrating green fluorescent protein (GFP) expression. Among the Jurkat cells, 57.1% showed GFP expression post-transduction, of which 34.1% showed surface expression of anti-PSMA CAR. Clonal expansion on the FBS-coated matrix proved effective, yielding 92.1% GFP-positive isolated cells. Functional assays demonstrated that CAR-T cells co-cultured with LNCaP cells exhibited significantly enhanced proliferation, activation (as indicated by CD69 and CD25 expression), and cytokine release assay (IFN-γ) compared with those co-cultured with DU 145 and mock cells.</p><p><strong>Conclusion: </strong>This new approach is efficient, economical, and scalable for isolating specific homogenous T cells and promoting their clonal proliferation and expansion. Furthermore, this method improves T cell adherence, proliferation, and functional effectiveness, offering a potential foundation for advancing CAR-T cell therapies aimed at solid tumors. Future research should concentrate on optimizing culture conditions and testing this method in preclinical animal models to ensure its clinical applicability and efficacy.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"15 1","pages":"133-142"},"PeriodicalIF":3.1000,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235364/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced pharmaceutical bulletin","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/apb.43798","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: T cell-based immunotherapy, especially chimeric antigen receptor (CAR)-T cells, has emerged as an appropriate approach for treating hematologic malignancies and is currently under investigation in clinical trials for solid tumors. Despite significant improvements in CAR-T cell production processes, the isolation and expansion of CAR-engineered T cells continue to pose significant challenges. The aim of this research is to provide a simple and cost-effective method for the isolation and expansion of human CAR-T cells. This novel concept applies coated fetal bovine serum (FBS) culture plates and focuses on enhancing viability and functionality to improve the adherence of suspended T cells.

Methods: This study evaluated a two-dimensional (2D) culture technique for isolating the CAR-T cells that target prostate-specific membrane antigen (PSMA) utilizing matrices pre-coated with 0.2% glutaraldehyde and FBS. Jurkat cells were transduced with a lentiviral vector encoding the anti-PSMA CAR construct. FBS-coated and commercialized Matrigel-coated matrices were used for single-cell isolation and clonal expansion. Functional tests were conducted to assess the activation and proliferation of CAR-T cells and the IFN-γ release assay subsequent to cloning and expansion.

Results: Transfection efficiency markedly improved, with 88.4% of Lenti-X 293T cells demonstrating green fluorescent protein (GFP) expression. Among the Jurkat cells, 57.1% showed GFP expression post-transduction, of which 34.1% showed surface expression of anti-PSMA CAR. Clonal expansion on the FBS-coated matrix proved effective, yielding 92.1% GFP-positive isolated cells. Functional assays demonstrated that CAR-T cells co-cultured with LNCaP cells exhibited significantly enhanced proliferation, activation (as indicated by CD69 and CD25 expression), and cytokine release assay (IFN-γ) compared with those co-cultured with DU 145 and mock cells.

Conclusion: This new approach is efficient, economical, and scalable for isolating specific homogenous T cells and promoting their clonal proliferation and expansion. Furthermore, this method improves T cell adherence, proliferation, and functional effectiveness, offering a potential foundation for advancing CAR-T cell therapies aimed at solid tumors. Future research should concentrate on optimizing culture conditions and testing this method in preclinical animal models to ensure its clinical applicability and efficacy.

基于fbs包被板的人CAR-T细胞单细胞克隆优化方法
目的:基于T细胞的免疫疗法,特别是嵌合抗原受体(CAR)-T细胞,已经成为治疗血液系统恶性肿瘤的一种合适的方法,目前正在实体瘤的临床试验中进行研究。尽管CAR-T细胞的生产工艺有了重大改进,但CAR-T细胞的分离和扩增仍然面临重大挑战。本研究的目的是为人类CAR-T细胞的分离和扩增提供一种简单而经济的方法。这个新概念应用于包被胎牛血清(FBS)培养板,并着重于提高生存能力和功能,以改善悬浮T细胞的粘附性。方法:本研究评估了一种二维(2D)培养技术,用于分离靶向前列腺特异性膜抗原(PSMA)的CAR-T细胞,该技术利用预先包被0.2%戊二醛和FBS的基质。用慢病毒载体编码抗psma CAR构建体转染Jurkat细胞。采用fbs包被和商业化的matrigel包被基质进行单细胞分离和克隆扩增。进行功能测试以评估CAR-T细胞的激活和增殖以及克隆和扩增后的IFN-γ释放试验。结果:转染效率显著提高,88.4%的lti - x 293T细胞表达绿色荧光蛋白(GFP)。57.1%的Jurkat细胞转导后表达GFP,其中34.1%的Jurkat细胞表面表达抗psma CAR。在fbs包被的基质上克隆扩增证明是有效的,获得92.1%的gfp阳性分离细胞。功能分析表明,与LNCaP细胞共培养的CAR-T细胞相比,与DU 145和模拟细胞共培养的CAR-T细胞的增殖、活化(CD69和CD25表达)和细胞因子释放(IFN-γ)均显著增强。结论:该方法可高效、经济、可扩展地分离特异性同质T细胞并促进其克隆增殖和扩增。此外,该方法提高了T细胞的粘附、增殖和功能有效性,为推进针对实体肿瘤的CAR-T细胞治疗提供了潜在的基础。未来的研究应集中在优化培养条件和临床前动物模型上,以确保该方法的临床适用性和有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advanced pharmaceutical bulletin
Advanced pharmaceutical bulletin PHARMACOLOGY & PHARMACY-
CiteScore
6.80
自引率
2.80%
发文量
51
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信